Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|EAQ191||ECOG-ACRIN||Cancer Therapy Risk-Reduction with Intensive Systolic BP Management (CARISMA) – a Phase II Study||Cancer Prevention and Control CIRB||Available to Open|
|EA4181||ECOG-ACRIN||A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients ≤ 70 years old with Untreated Mantle Cell Lymphoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|GOG-0262||GOG||GOG-0262: A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel In Combination With Carboplatin With Or Without Concurrent and Consolidation Bevacizumab (NSC #704865; IND #113912) in the Treatment of Primary Stage II; III OR IV Epithelial Ovarian; Peritoneal or Fallopian Tube Cancer and ACRIN 6695: Perfusion CT Imaging To Evaluate Treatment Response in Patients Participating in GOG-0262||Adult CIRB - Late Phase Emphasis||Available to Open|
|10096||ETCTN||A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer with Bone Metastases (COMRADE)||Adult CIRB - Early Phase Emphasis||Available to Open|
|AEWS1031||COG||A Phase III Randomized Trial of Adding Vincristine-topotecan-cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma: A Groupwide Phase III Study||Pediatric CIRB||Available to Open|
|S1314||SWOG||A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized; Muscle-Invasive Bladder Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|A031702||Alliance||A Phase II Study of Ipilimumab, Cabozantinib, and NIvolumab in Rare Genitourinary Cancers (ICONIC)||Adult CIRB - Late Phase Emphasis||Available to Open|
|9767||ETCTN||An Open Label; Multicenter; Single arm Phase II study to evaluate the Activity and Tolerability of the novel mTOR Inhibitor; MLN0128 (TAK-228); in patients with Locally Advanced or Metastatic Transitional Cell Carcinoma of the urothelial tract whose tumors harbor a TSC1 and/or a TSC2 mutation||Adult CIRB - Early Phase Emphasis||Available to Open|
|APEC1621-MASTER||COG||NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Study||Pediatric CIRB||Available to Open|
|EA1151||ECOG-ACRIN||Tomosynthesis Mammographic Imaging Screening Trial (TMIST)||Cancer Prevention and Control CIRB||Available to Open|